Search the Newsreel

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Amylyx Pharmaceuticals (NASDAQ:AMLX) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $25.38. Despite a recent quarterly loss that missed estimates, analysts generally maintain a positive outlook, with several increasing their price targets. Institutional investors hold a …

Is Amylyx (AMLX) Quietly Rewriting Its R&D Risk‑Reward Profile As Losses Deepen Without Revenue?

Amylyx Pharmaceuticals (AMLX) reported a widening net loss in Q2 2026, reaching US$43.42 million, and a six-month net loss of US$84.71 million, even though basic loss per share slightly narrowed. This indicates increasing development costs for its pipeline without corresponding revenue. The company's investment …

HC Wainwright Issues Pessimistic Outlook for AMLX Earnings

HC Wainwright Has Bearish Forecast for AMLX FY2029 Earnings

Dimensional Fund Advisors LP Has $12.54 Million Stock Holdings in Amylyx Pharmaceuticals, Inc. $AMLX

Dimensional Fund Advisors LP significantly increased its stake in Amylyx Pharmaceuticals (NASDAQ:AMLX) by 17.1% in the first quarter, now holding 903,192 shares valued at $12.54 million. Despite institutional interest, Amylyx shares traded down 5.7% after opening and missed analysts' EPS estimates for the quarter. …

Amylyx Pharmaceuticals Inc (AMLX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Amylyx Pharmaceuticals, Inc. (AMLX) Stock Price, News, Quote & History

This Yahoo Finance page provides comprehensive information on Amylyx Pharmaceuticals, Inc. (AMLX), including its current stock price, recent news, historical data, and financial performance. It details the company's focus on developing treatments for neurodegenerative and endocrine conditions, highlighting its pipeline of clinical-stage products. The …

Amylyx Pharmaceuticals (AMLX) Could Be 5% Undervalued After Second Quarter Earnings

Amylyx Pharmaceuticals Releases Q2 2026 Financial Results

Amylyx Pharmaceuticals (AMLX) reported a Q2 2026 net loss of $0.39 per share, wider than the $0.37 expected loss, totaling $43.4 million. Despite missing analyst expectations, the company showed a 15.2% improvement from the Q2 2025 loss of $0.46 per share. Wall Street maintains …

Amylyx Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $26.7, Implies 22% Upside

Amylyx Pharmaceuticals, Inc. (AMLX) has seen its average 12-month price target raised from $25.56 to $26.7 by 10 analysts, suggesting a 22% potential upside from its August 5th closing price. The consensus rating remains a "Buy" from 11 analysts, with 10 recommending "Buy" and …

Amylyx Pharmaceuticals Narrows Q2 2026 Loss to -$0.39/Share

Amylyx Pharmaceuticals reported a wider-than-expected net loss of $0.39 per share for Q2 2026, missing the Street's estimate of $0.37, yet this represented a 15.2% improvement from the prior year. Despite the miss, the stock remained flat, and analysts maintain a bullish outlook with …

Amylyx Pharmaceuticals Q2 Earnings Call Highlights

Amylyx Pharmaceuticals expects top-line data from its pivotal Phase III LUCIDITY trial for avexitide in post-bariatric hypoglycemia (PBH) by early September. The company is preparing for a potential U.S. launch in 2027, contingent on positive data and regulatory approval, and is also advancing other …

Amylyx Pharmaceuticals 2Q Loss/Shr 39c >AMLX

Amylyx Pharmaceuticals reported a second-quarter loss per share of 39 cents. This financial update is significant for investors following the company's performance. The results provide insight into the company's recent financial health.

Amylyx Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary

Amylyx Pharmaceuticals, Inc. has released its earnings summary for the quarter that ended on June 30. The article, sourced from Reuters via TradingView News, indicates that this report provides key financial results for the company during that period.

Amylyx Pharmaceuticals (NASDAQ:AMLX) Issues Earnings Results, Misses Estimates By $0.03 EPS

Amylyx Pharmaceuticals Inc expected to post a loss of 36 cents a share - Earnings Preview

Amylyx Pharmaceuticals Inc is projected to report a loss of 36 cents per share, according to a recent earnings preview. The article, sourced from Reuters via TradingView News, indicates this financial expectation for the company.

Amylyx Pharmaceuticals earnings up next as trial data looms

Amylyx Pharmaceuticals is set to report Q2 earnings, with analysts anticipating narrowed losses but with primary focus on the imminent Phase 3 LUCIDITY trial data, expected in Q3 2026. The trial, evaluating avexitide for post-bariatric hypoglycemia, is considered a pivotal moment for the pre-revenue …

Amylyx Ongoing Deadline Alert

Faruqi & Faruqi, LLP is investigating potential claims against Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) and reminds investors of the April 9, 2024 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit. The firm alleges that Amylyx overstated the …

Amylyx will discuss second-quarter results in Aug. 6 webcast

Janus Henderson Group PLC Has $69.26 Million Stock Holdings in Amylyx Pharmaceuticals, Inc. $AMLX

Amylyx Pharmaceuticals Inc (AMLX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Amylyx Pharmaceuticals Inc (AMLX), covering its current price momentum score, support and resistance levels, and various technical indicators. It details the readings for MACD, RSI, KDJ, ATR, CCI, Williams %R, TRIX, and StochRSI, along with moving averages …

Amylyx Pharmaceuticals Inc (AMLX) Financial Health: Profitability & Balance Sheet Analysis

Amylyx Pharmaceuticals Inc (AMLX) has a weak financial status with a score of 5.42, ranking 360 out of 384 in its industry. The company's operational efficiency is low, and key financial data for metrics like cash and cash equivalents, total revenue, and free cash …

Amylyx Pharmaceuticals Inc (AMLX) Institutional Confidence

Amylyx Pharmaceuticals Inc (AMLX) has an institutional shareholding score of 10.00, placing it at the top of the Biotechnology & Medical Research industry. Institutional shareholding proportion increased by 5.01% quarter-over-quarter, reaching 104.12%. Fidelity Management & Research Company LLC is a significant institutional shareholder, increasing …

Amylyx Pharmaceuticals Inc (AMLX) Cash Flow

This article provides a detailed cash flow statement for Amylyx Pharmaceuticals Inc (AMLX), covering quarterly and annual data from FY2020Q4 to FY2026Q1 across operating, investing, and financing activities. It presents financial figures in USD, highlighting net income, capital expenditures, and changes in working capital. …

Amylyx Pharmaceuticals Inc (AMLX) Valuation: PE, PB & Fair Value Analysis

Amylyx Pharmaceuticals Inc (AMLX) has a current valuation score of 8.13, placing it 163rd out of 386 in the Biotechnology & Medical Research industry. Its P/E ratio stands at -13.13, which is significantly below its recent high but above its recent low. The company …

Amylyx Pharmaceuticals, Inc. $AMLX is First Light Asset Management LLC's 7th Largest Position

Amylyx Pharmaceuticals Inc (AMLX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Amylyx Pharmaceuticals Inc (AMLX), outlining its major shareholders and categories of institutional holdings. It provides a breakdown of proportional ownership by investment firms, hedge funds, and other investor types, alongside a historical view of institutional shareholdings and …

Amylyx Pharmaceuticals Inc (AMLX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Amylyx Pharmaceuticals Inc (AMLX) stock performance and its dividend history. It states that the company has not distributed any dividends over the past five years and contains no data on past dividend or stock split events. The page …

Amylyx Pharmaceuticals Inc (AMLX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides details on the revenue breakdown for Amylyx Pharmaceuticals Inc (AMLX), although it states that relevant data for business segments and regional revenue have not yet been disclosed by the company. It lists various fiscal years for which data is expected, such …

AMLX|Amylyx Pharmaceuticals Inc|Price:18.410|Chg%:+0.820

Amylyx Pharmaceuticals Inc. (AMLX) shows relatively weak fundamentals but high growth potential, with its valuation considered fairly valued within the Biotechnology & Medical Research industry. Institutional ownership is very high, and analysts currently rate it as "Buy" with a median target price of $24.889, …

Mizuho Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $24

Mizuho Securities has reiterated its Buy rating on Amylyx Pharmaceuticals (AMLX.US) and increased its target price to $24. This adjustment reflects the firm's continued positive outlook on the company's prospects.

Mizuho Raises Price Target on Amylyx Pharmaceuticals to $24 From $21, Keeps Outperform Rating

Mizuho has increased its price target for Amylyx Pharmaceuticals (NASDAQ: AMLX) from $21 to $24, while maintaining an "Outperform" rating on the stock. This adjustment reflects a positive outlook from the analyst firm on the biotechnology company.

Mizuho raises Amylyx stock price target to $24 ahead of trial data

Mizuho has increased its price target for Amylyx Pharmaceuticals (AMLX) to $24 from $21, maintaining an Outperform rating, due to increased confidence in the company's avexitide treatment. The firm raised its probability of success for positive Phase 3 data for avexitide in postbariatric hypoglycemia …